Kymera Q4 revenue misses expectations, net loss widens

Reuters

Feb 26

Kymera Q4 revenue misses expectations, net loss widens

Overview

Biopharmaceutical firm's Q4 revenue missed analyst expectations
Net loss for Q4 widened compared to the previous year
Company ended 2025 with $1.6 bln cash, runway into 2029

Outlook

Kymera expects data from KT-621 Phase 2b trials in mid-2027 and late-2027
Company anticipates KT-579 Phase 1 trial data in second half of 2026
Kymera projects cash runway into 2029 with $1.6 bln in cash

Result Driver

R&D EXPENSES - Increased due to investment in STAT6 program and discovery initiatives

Company press release: ID:nGNXc5PvnQ

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Miss	$2.87 mln	$15.05 mln (20 Analysts)
Q4 EPS		-$0.97
Q4 Net Income		-$86.98 mln
Q4 Operating Expenses		$100.77 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Kymera Therapeutics Inc is $116.00, about 27.9% above its February 25 closing price of $90.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614404983"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614404983\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614404983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614404983","market":"nz","top_or_hot":-1,"title":"Kymera Q4 revenue misses expectations, net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kymera Q4 revenue misses expectations, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue missed analyst expectations</p></li><li><p>Net loss for Q4 widened compared to the previous year</p></li><li><p>Company ended 2025 with $1.6 bln cash, runway into 2029</p></li></ul><p><span>Outlook</span></p><ul><li><p>Kymera expects data from KT-621 Phase 2b trials in mid-2027 and late-2027</p></li><li><p>Company anticipates KT-579 Phase 1 trial data in second half of 2026</p></li><li><p>Kymera projects cash runway into 2029 with $1.6 bln in cash</p></li></ul><p><span>Result Driver</span></p><ul><li><p>R&amp;D EXPENSES - Increased due to investment in STAT6 program and discovery initiatives</p></li></ul><p>Company press release: <span>ID:nGNXc5PvnQ</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Miss</p></td><td><p>$2.87 mln</p></td><td><p>$15.05 mln (20 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.97</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$86.98 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$100.77 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 22 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $116.00, about 27.9% above its February 25 closing price of $90.68</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kymera Q4 revenue misses expectations, net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKymera Q4 revenue misses expectations, net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kymera Q4 revenue misses expectations, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue missed analyst expectations</p></li><li><p>Net loss for Q4 widened compared to the previous year</p></li><li><p>Company ended 2025 with $1.6 bln cash, runway into 2029</p></li></ul><p><span>Outlook</span></p><ul><li><p>Kymera expects data from KT-621 Phase 2b trials in mid-2027 and late-2027</p></li><li><p>Company anticipates KT-579 Phase 1 trial data in second half of 2026</p></li><li><p>Kymera projects cash runway into 2029 with $1.6 bln in cash</p></li></ul><p><span>Result Driver</span></p><ul><li><p>R&amp;D EXPENSES - Increased due to investment in STAT6 program and discovery initiatives</p></li></ul><p>Company press release: <span>ID:nGNXc5PvnQ</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Miss</p></td><td><p>$2.87 mln</p></td><td><p>$15.05 mln (20 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.97</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$86.98 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$100.77 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 22 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is $116.00, about 27.9% above its February 25 closing price of $90.68</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0LV:1","article_id":"2614404983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614404983","pubTimestamp":1772108602,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kymera Q4 revenue misses expectations, net loss widensOverviewBiopharmaceutical firm's Q4 revenue missed analyst expectationsNet loss for Q4 widened compared to the previous yearCompany ended 2025 wit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Kymera第四季度营收未达预期，净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":0.9},"content_text":"Kymera Q4 revenue misses expectations, net loss widensOverviewBiopharmaceutical firm's Q4 revenue missed analyst expectationsNet loss for Q4 widened compared to the previous yearCompany ended 2025 with $1.6 bln cash, runway into 2029OutlookKymera expects data from KT-621 Phase 2b trials in mid-2027 and late-2027Company anticipates KT-579 Phase 1 trial data in second half of 2026Kymera projects cash runway into 2029 with $1.6 bln in cashResult DriverR&D EXPENSES - Increased due to investment in STAT6 program and discovery initiativesCompany press release: ID:nGNXc5PvnQKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueMiss$2.87 mln$15.05 mln (20 Analysts)Q4 EPS-$0.97Q4 Net Income-$86.98 mlnQ4 Operating Expenses$100.77 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 22 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Kymera Therapeutics Inc is $116.00, about 27.9% above its February 25 closing price of $90.68For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}